Connect your AI

aTyr Pharma ATYR Operating Cash Flow

Operating Cash Flow at other companies

Bristol-Myers SquibbBMY

$1.1B-43.5%

Merck & Co.MRK

$3.92B+56.7%

United TherapeuticsUTHR

$463.3M+0.5%

Design Therapeutics, Inc.DSGN

-$16.43M+2.1%

Oric Pharmaceuticals, Inc.ORIC

-$32.44M+0.3%

Vor BiopharmaVOR

-$38.25M-23.1%

Other financials

Income statement

Revenue-—

Operating income-$11.4M+27.5%

Net income-$10.8M+27.5%

EPS (diluted)-$0.11+35.3%

Balance sheet

Cash & equivalents$10.0M-3.4%

Total debt$12.3M-9.2%

Total equity$57.9M-22.8%

Total assets$79.7M-18.1%

Cash flow

CapEx$138.0K—

Free cash flow-$12.7M+17.9%

Valuation

Market cap$54.88M-88.2%

Enterprise value$57.17M—

P/S288.8×—

Profitability

Operating margin-40,856.3%+28,833pp

Net margin-39,009.5%+29,653pp

FCF margin-32,664.7%+4,018pp

Returns & leverage

Return on equity-105.3%+50.6pp

Debt / equity0.2×0.0×

Current ratio5.8×-2.0×

Where this comes from

Reported directly by aTyr Pharma in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: aTyr Pharma’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about aTyr Pharma's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is aTyr Pharma's operating cash flow?: aTyr Pharma (ATYR) reported operating cash flow of -$12.52M in Q1 2026.
How has aTyr Pharma's operating cash flow changed year-over-year?: aTyr Pharma's operating cash flow increased by 18.8% year-over-year, from -$15.42M to -$12.52M.
What is the long-term trend for aTyr Pharma's operating cash flow?: Over 4 years (2021 to 2025), aTyr Pharma's operating cash flow has grown at a 17.0% compound annual growth rate (CAGR), from -$33.08M to -$61.99M.
What does operating cash flow mean?: Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.